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The Anticoagulant Mechanism of Action
of Recombinant Hirudin (CGP 39393) in Plasma
Theo L indhout .  Ron Blezer ,  and H.  Coenraad Hemker
From the Department of Biochemistry, University of Limburg, Maastricht,
The Nether lands
Summary
We studied the inhibitory action of recombinant desul-
phatohirudin (CGP 39393) on thrombin generation in whole
plasma. Human plasma was activated either with thromboplastin
or factor IXa. Hirudin delayed thrombin generation, but it was
unable to prevent the explosive appearance of thrombin. The
dose-dependent prolongation of the lag phase of the intrinsic and
extrinsic thrombin generation curve was not the result of titration
of thrombin activity by hirudin but the result of a delayed
formation of the prothrombin converting complex (prothrombin-
ase). In case of extrinsic activation, hirudin did not affect
factor Xa generation, but prolonged the lag phase of the fac-
tor Va generation curve, causing its appearance when factor Xa
generation was already in the decay phase. Because of its
inhibitory action on the thrombin-mediated activation of factor
VIII, hirudin prolonged the lag phase of the factor X converting
complex that consists of factor IXa and factor VIIIa. Our obser-
vations with hirudin are in keeping with the notion that inhibition
of the thrombin-mediated amplification reactions in blood coagu-
lation is a very efficient way to delay or inhibit completely
thrombin generation. However, although hirudin neutralizes
stoichiometric amounts of thrombin, the interaction between in
situ generated thrombin and hirudin appears not to be fast enough
to prevent trace amounts of thrombin to activate factors Vlll
and V. Consequently, an explosive thrombin generation is ob-
served even when free hirudin is present.
lntroduction
Hirudin is a very selective tight binding inhibitor of thrombin
(1). The dissociation constant of the complex between thrombin
and hirudin, isolated from the salivary gland of the leech Hirudo
medicinalis, has been reported to be 20 fM (2). The recombinant
desulphatohirudin CGP 39393 has a 1O-fold lower affinity for
thrombin (3). Thus, thrombin activity will be neutralized by
hirudin in stoichiometric amounts at extremely low concentra-
tions of both reactants. This makes hirudin the most potent and
specific inhibitor of thrombin known. Whether this property can
make hirudin a highly potent in vitro anticoagulant in the subject
of our present study.
Blood coagulation has to be considered as a process that is
controlled by complex feedback systems (a). An essential charac-
teristic of such a system is that small changes in stimulus level can
cause very large changes in the response. It is becoming increas-
ingly apparent that the final product of the blood coagulation
process, thrombin, is such a feedback stimulus. Activated fac-
tor IX and activated factor X are enzymes with low k.o, and high
K- values in their reactions with factor X and prothrombin,
respectively. In the presence of their respective cofactors (factor
Correspondence to: Dr. Th. Lindhout, Dept. of Biochcmistry, Univer-
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VIIIa or factor Va) and a procoagulant surface (activated blood
platelets), factor IXa and factor Xa become very efficient en-
zymes and it is only then, that factor Xa and thrombin are
produced at high rates (5, 6). Interestingly, thrombin has been
demonstrated to be the only activator of both factor V and
factor VIII in thromboplastin-activated plasma (7). Moreover,
small amounts of thrombin, generated under the influence of
trace amounts of tissue factor, were shown to induce procoagulant
activity in blood platelets (8). Thus, in view of the tight-binding
nature of the interaction between thrombin and hirudin, one
might expect that low concentrations of hirudin will prevent the
generation of cofactors and thus the explosive generation of
thrombin. However, two points remain to be clarified. Firstly, it
cannot be excluded that when a potent thrombin inhibitor is
present, activated factor X starts to play a role in the generation
of factor VIIIa (9). Secondly, the binding of hirudin to thrombin
involves at least two steps: ionic interaction at a site distinct from
the active site of thrombin followed by a rearrangement of the
complex to form a tighter complex in which hirudin is also (non-
covalently) bound to the active site (10). Therefore, besides the
extremely high affinity of thrombin for hirudin, the rate of
interaction and the effects of other substrates for thrombin on that
rate have also to be taken into account, because they might
determine to a large extent the anticoagulant potency of hirudin.
In this paper we wish to report on hirudin and its dose-
dependent effect on thrombin generation in thromboplastin- and
factor IXa-activated whole plasma By monitoring the generation
of activated clotting factors at stages before thrombin, we were
able to identify the rate limiting steps that determine the overall
rate of thrombin generation in the presence of hirudin. lt is
demonstrated that hirudin at a concentration equivalent to the
amount of thrombin formed before the plasma clots, is not
sufficient to achieve an anticoasulant effect.
Materials and Methods
The synthetic peptide substrate Bz-Ile-Glu-(piperidyl)-Gly-Arg-p-
nitroanilide hydrochloride (S-2337) and H-D-Phe-Pip-Atg-p-nitroanalide
hydrochloridc (5-2238) were purchased from AB Kabi Vtrum, Sweden.
Fatty acid-free human serum albumin was a product of Sigma Chemical
Co , St Louis Rccombinant desulphato-hirudin variant 1 (CGP 39393)
was kindly provided by Dr Wallis, Ciba-Geigy, Horsham, UK. Human
brain thromboplastin was prcpared by the method of Owren and Aas (11).
Its concentration was adjusted with Tiis-saline to give a prothrombin time
(PT) of 13 s. All reagents used werc of the highest grade commercially
available.
Purification of proteins Bovine coagulation factor IXa and human
coagulation factor X, prothrombin and thrombin were prepared and
quantitated as previously described (12, 13) Staphylocoagulase was
purif ied by thc method described by Hendrix et al.  (14).
Preparation of human normal plasma. Blood from healthy donors was
collected on 0.13 M trisodium citrate; nine parts of blood to one part of
anticoagulant. The blood was ccntrifugated twice at room temperature for
15 min at 3,000 x g. A third centrifugation was done at 4'C for t h at
23,000 x g The obtained platelet free plasma was stored at -80" C
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Fig I Generation of activatcd clotting factors in thromboplastin acti-
vatcd plasma. Panel A: thrombin generation (O) and prothrombin
consumption (A); panel B: factor Xa (O) and factor Va (A) generation.
The values are expressed as a percentage of the maximum amounts, i e.
340 nM thrombin, 1.0 pM prothrombin, 25 nM factor Va, 3 nM fac-
tor Xa. The detailed experimental conditions are described undcr Mate-
rials and Methods
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phospholipid (1 mM; 20 mol"/" phosphatidylserine/8O mol% phos-
phatidylcholine), followed by the addition of 7.5 pl of a factor IXa
solution (1 pM) and 6 pl CaCl2 (0 5 M) Thc plasma clotting time in thc
absence of hirudin was 120 s All plasma experiments wcre pcrformcd at a
free Ca2+ concentration of 4 mM, as measured with a calcium-spccific
electrode standardized with CaCl2 in Tiis-buffer
Monitoring the generation o.f activated clotting factors. At timed
intewals, samples (5 pl) were removed from thc activated plasma and
assayed fbr factor Va, factor Xa, factor VIIIa and thrombin using specific
bioassays and synthetic chromogenic substrates as previously described (7,
15). When thrombin was assayed by an amidolytic method, final and
sustaining levels of thrombinlike activity were measured as a result of the
formation of amidolytic active n2-macroglobulin-thrombin complexes In
ordcr to obtain generation curves of free thrombin, we corrected our
thrombin measurcmcnts according to the method described by Hemker et
a l .  (16).
Briefly, because o2-macroglobulin is present in plasma in large excess
ovcr free thrombin (T), the formation of thrombin/o2-macroglobulin
complex (orM.T) follows pscudo first order reaction kinetics:
d(ozM T)idt : kzT
k2 was determincd as in ref. 16 and equals 0.25 min I , independent of the
hirudin conccntration. Frcc thrombin (T) at any time point (t) is then
calculated from the experimentally determined amidolytic activity at that
time point (A,) according to
Tt :  At- f (uzM.T)t
whcrc f is the ratio of the amidolytic activity of 1 molc of a2M.T over that
of 1 molc of frcc thrombin, having a value of 0.56 (16) The correctncss of
the procedure and of thc numerical value of k2 was found in the
observation of a zcro end level of thrombin.
Measurement of prothrombin consumption Activated plasma samples
(5 pl) wcrc incubated with 20 pl of Tris (50 mM), NaCl (175 mM), 0.5 mg
human scrum albumin/ml, pH 7.9 containing 20 mM EDTA and 5 pg
heparin/ml An aliquot of 10 pl was transferred to a cuvette containing
Tiis-buffer and 5-2238 (0.2 mM) to determine the amount of thrombin
complexed with o2-macroglobulin. Another 10 pl-aliquot of the first
incubation mixture was incubatcd with staphylocoagulase (0.5 pM) for
2 min Thc activity formed as a result of thc stoichiometric interaction
between prothrombin and staphylocoagulase was measured using S-2238
as described. The amount of prothrombin in the activated plasma samplc
was then calculated from the differcncc between both determinations. A
standard curvc was constructed from known amounts of purified human
prothrombin.
Results
T hr o mb op las tin- Activ ate d P las ma
Incubation of citrated plasma with thromboplastin and free
calcium ions (4 mM) under the conditions as described in
Materials and Methods, resulted after a short lag phase in a
sudden onset of thrombin generation, followed by a decay phase
(Fig. 1A). Values are given as percentage of the thrombin peak
value
Obviously, the somewhat delayed thrombin generation is the
result of a delayed onset of prothrombin conversion (Fig. 1,.A.).
From Fig.lB it becomes evident that the rapid conversion of
prothrombin is related to the appearance of factor Va, and not at
all to that of factor Xa. This is in keeping with the notion that
significant amounts of thrombin can only be generated when the
prothrombin converting complex (prothrombinase), that consists
of activated factor X and activated factor V assembled at a
phospholipid surface, is formed. Thus, the delayed (30 s) appear-
ance of factor Va is the rate limiting step in the formation of the
prothrombinase complex and regulates the onset of thrombin
generation.
The same experiment, but than performed in the presence of
hirudin (450 nM), clearly showed that hirudin had two effects on
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Fig.2 Effect of hirudin on the generation of activated clotting factors in
thromboplastin-activated plasma. The same experimental conditions as in
Fig 1, but in the presence of 450 nM hirudin. Panel A: thrombin
generation (O) and prothrombin consumption (A); panel B: factor Xa
(O) and factor Va (A) generation
Initiation of the extrinsic and intrinsic pathway of plasma clotting. 135 1tl
of citrated human plasma was supplemented with 4 pl of Tiis-buffer
(50 mM'Tiis-HCl, I75 mM NaCl, 0.5 mg human serum albumin/ml,
pH 7 .9) with or without hirudin, and incubated for 2 min in a flat-bottom
plastic tube while stirring The plasma was activated by the addition of
6 pl CaCl2 (0.5 M) and 5 pl of human brain thromboplastin. The clotting
time in thc absence of hirudin was 45 s.
Intrinsic activation of plasma was performed by incubation of 130 pl of
plasma with 3.5 pl of Tiis-buffer with or without hirudin and 3 pl
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delayed the appearance of factor Va but not that of factor Xa.
Evidently, factor Xa is not involved in the generation of fac-
tor Va, thus inhibition of factor Va generation is solely caused by
the hirudin-dependent inhibition of the first traces of thrombin. If
so, one expects the onset of thrombin generation after all hirudin
is complexed with thrombin. According to the prothrombin
consumption measurements (Fig.2A), onset of thrombin genera-
tion was observed when 25o/" of the prothrombin was converted
and thus 250 nM thrombin generated. These findings suggest that
during in situ thrombin generation, traces of thrombin that are
not neutralized by hirudin trigger further thrombin generation by
activation of factor V.
To test this hypothesis, the following experiments were per-
formed. Plasma was incubated with thromboplastin in the pres-
ence of 600 nM hirudin. The onset of thrombin generation was
seen at 10 min (Fig.3). Addition of purified human o-thrombin
(150 nM), 3 min after thromboplastin/calcium, caused an instan-
tenous generation of thrombin activity and plasma clot formation.
Thus, although hirudin is present in excess over the amount of
thrombin added, a true burst of thrombin activity is seen. In fact,
most of the thrombin added was immediately neutralized as found
by rapid subsampling (every 5 s). This is more clearly seen when
less thrombin (75 nM) is added. The thrombin activity gradually
increased until a burst. These findings suggest that part of the
exogenous thrombin survives the inhibitory action of hirudin long
enough to activate factor V. At both exogenous thrombin con-
centrations complete activation of plasma factor V was observed
(data not shown).
Factor I Xa-Activ ated Plasma
Increasing amounts of hirudin added to plasma that was
incubated with factor IXa, phospholipid and calcium, caused a
dose-dependent prolongation of the lag phase of the free-
thrombin generation curve. In addition, reduced peak values of
free thrombin concentrations were observed (Fig'aA). Fig.48
shows that prothrombin consumption is negligable before the
burst of thrombin activity. These observations are qualitatively
not different from those found when plasma was activated with
thromboplastin. However, from Fig.5 it becomes apparent that
the lag phase of the factor IXa-induced thrombin generation
curve is caused by a different mechanism. In spite of the relative
high amount of factor IXa added to the plasma, factor Xa
generation did show a lag phase (Fig.sA). Apparently, fac-
tor IXa, even at a concentration half the plasma level of
factor IX, is unable to generate factor Xa at a significant rate.
From Fig.58 it becomes clear that the rate limiting step in the
generation of the factor X converting complex is the generation of
the cofactor (factor VIIIa). Hirudin dramatically increased the
lag time of factor Xa generation. This finding strongly suggests
that neutralization of thrombin by hirudin caused the observed
delay in factor VIIIa generation. However, it is in that case not
easy to conceive how a burst of thrombin activity could occur.
From the prothrombin consumption curves (Fig.48) it is clearly
seen that prior to the time point of the sudden onset of an
extremely rapid prothrombin consumption much less thrombin
has been generated than the amount of free hirudin initially
present. The areas under the thrombin generation curves
decreased proportionally with increasing hirudin concentrations,
indicating that most of the hirudin is consumed after the sudden
onset ofthrombin generation (Fig.4). These observations point at
a role of factor Xa in the activation of factor VIII when thrombin
activity is blocked by hirudin.
This notion was tested in the following way. The addition of
factor Xa to plasma that was incubated for 1 min with factor IXa,
almost immediately caused a burst of factor Xa activity (Fig.6).
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Fig.3 Exogenous thrombin and thrombin generation in plasma containl
ing hirudin Plasma was activated with thromboplastin in the presence of
600 nM hirudin as described. Three min later the following additions were
made: 150 nM human o-thrombin (O), 75 nM human cr-thrombin (O) or
none (A)
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Fig 4 Effect of hirudin on the generation of thrombin (panel A) and
prothrombin consumption (panel B) in factor IXa-activated plasma. Sym-
bols indicate: (O) in the absence of hirudin, (a) 150 nM hirudin, and (A)
300 nM hirudin
thrombin generation when free thrombin concentration is ex-
pressed as percentage of the free thrombin peak value in the
absence of hirudin (Fig.2A). Firstly, a markedly increased lag
phase of thrombin generation is seen, which reflects the prolonga-
tion of the plasma clotting from 45 s in the absence of hirudin to
8 min in the presence of 450 nM hirudin. Secondly, the amount of
free thrombin that could be generated is greatly reduced. Both
observations could be explained by assuming a simple titration
phenomenon in which the first amounts of thrombin formed are
neutralized by hirudin. llowever, the prothrombin consumption
curve (Fig.2A) shows that at the time of rapid onset of thrombin
generation, the rate of prothrombin conversion increased drasti-
cally. Apparently, the increased lag phase of the thrombin
generation curve is the result of the inhibitory action of hirudin on
the reactions that are involved in the generation of the prothrom-
binase complex.
When we compare the effect of hirudin on factor Xa genera-
tion and factor Va generation (Fig.2B) it is clear that hirudin
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Flg.5 Effect of hirudin on the generation of factor Xa (panel A),
factor VIIIa (panel B) and factor Va (panel C) in factor IXa-activated
plasma The symbols indicate: (O) in the absence of hirudin, (O) 150 nM
hirudin, and (A) 300 nM hirudin
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activation of factor VIII. In this respect it is important to note
that hirudin does prolong the lag phase of the factor Xa genera-
tion curve.
Discussion
Based upon our current knowledge of the remarkable proper-
ties of hirudin as a very specific and strong inhibitor of thrombin,
one might expect a simple anticoagulant mechanism of action of
this drug: neutralization of formed thrombin in stoichiometric
amounts. Consequently, it might be believed that the effective
dose of hirudin, as an antithrombotic drug, is the amount which
titrates the amount of thrombin generated in a given thrombotic
situation (17).
However, once coagulation is initiated, thrombin induces an
extremely powerful amplification of its own generation. Also, it
must be realized that a number of natural subtrates for thrombin
will compete with hirudin for the same site on thrombin If such a
competition exists, then the rate of interaction between thrombin
and hirudin should decrease; thereby rendering hirudin a slow-
binding inhibitor (18).
Our basic finding is that, at least during in vitro plasma
clotting, the anticoagulant potency of hirudin is less than one
might expect from a fast and tight-binding inhibitor of thrombin.
During extrinsic clotting in the presence of hirudin, a slow rate of
prothrombin consumption was observed before the onset of rapid
thrombin generation (Fig.2). However, it seems that rhe amo;nt
of prothrombin consumed (thus total thrombin generated) is still
less than the total amount of hirudin. The very same was observed
during factor IXa-induced thrombin generation. Before the sud-
den onset of thrombin generation, no significant prothrombin
consumption could be detected (Fig.a). Thus, at the time of
appearance of thrombin activity the effective hirudin concentra-
tion was not significantly diminished. Yet, an explosive burst of
thrombin activity was seen.
These observations are readily explicable by consideration of
the factors that determine the lag phase and the rate of prothrom-
bin consumption and thus prothrombinase formation. When
clotting is initiated by the addition of factor IXa, the only event
that determines the generation of factor Xa is the activation of
factor VIII, because factor IXa activity is not neutralized whether
or not hirudin is present (19).
From the extrinsic clotting experiments it is known that
generation of factor Xa alone is not sufficient to obtain a rapid
generation of thrombin. The rate limiting step in the generation of
the prothrombin converting complex (prothrombinase) is the
activation of factor V by thrombin (Fig.2 and refs 9, 15,20).
Indeed, small amounts (1 nM) of exogenous factor Va drastically
decreased the lag-time period of thrombin in factor IXa-activated
plasma (Lindhout, unpublished results) and addition of activated
factor VIII abolished the lag phase of thrombin generation, even
in the presence of heparin (20). Overall, the linked positive
feedback reactions by which the essential cofactors Va and VIIla,
are generated, tbrm the basis of a sudden onset of the generation
of the prothrombinase complex after a lag phase that is needed to
generate sufficient amounts of factor Xa and factor Va to build
the prothrombinase complex
The intriguing observation with hirudin is that this potent
thrombin inhibitor is unable to prevent the formation of the
prothrombinase complex, knowing that during the lag phase of
intrinsic clotting, thrombin is generated at a very slow rate.
During the lag phase of extrinsic clotting a higher rate of thrombin
generation was found because in this case the generation of
factor Xa is not inhibited. Therefore, it is not quite unexpected
that more hirudin is required to achieve an anticoagulant effect in
the latter case than in the former one.
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Fr,g. 6 Exogenous factor Xa and factor Xa generation in plasma contain-
ing hirudin. Plasma was activated with [factor IXa (50 nM), phospholipid(20 pM), free calcium ions (4 mM)] in the abscnce (O) or presence of
250 nM (O) and 500 nM (A) hirudin. Human factor Xa (1 nM) was added
1 min after factor IXa
When the same experiment was performed in the presence of
hirudin, the burst of factor Xa was delayed. However, the lag
time was drastically shortened: from 15 min in the presence of
300 nM hirudin and no factor Xa (Fig.58) to 3 min when 1nM
of factor Xa was added. Of interest is to note that the decay of
exogenous factor Xa is not affected by hirudin. Thus, whereas
these findings indicate that factor Xa is able to trigger its own
generation, it is not quite clear whether this is the result of a direct
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The unexpectedly low anticoagulant activity of hirudin can be
considered as follows. First of all, it is reasonable to assume that
thrombin is generated at a site where also factors V and VIII are
found, i. e. at or very close to the phospholipid surface (4). In that
case, thrombin might become less susceptible to the inhibitory
action of hirudin (protective effect). Furthermore, because of
their high local concentrations at the phospholipid surface,
factor V and/or factor VIII will show an increased competition
with hirudin for thrombin. We could demonstrate that the rate of
association of the interaction between hirudin and thrombin is
indeed too slow relative to the catalytic effeciency of the
thrombin-catalyzed factor V activation reaction. Alternatively, it
cannot be ruled out that factor Xa is able to generate sufficient
amounts of factor VIIIa to trigger its own generation. Such an
event will cause an increased thrombin production, which in turn
enhances the rates of factor Va and factor VIIIa generation and
finally ends in an explosive thrombin generation. Indeed, small
amounts of exogenous factor Xa were found to shorten, but not
to abolish, the lag phase of the factor Xa generation curve and
drastically diminished the hirudin-induced prolongation of that
lag phase. In the presence of 250 nM hirudin, 1 nM of factor Xa
added 1 min after factor IXa, shortened the lag phase from 10 to
3 min (Fig.6). As yet, it remains unclear to what extent factor Xa
is able to trigger its own generation by activation of factor VIIL
That is, the lag phase of the factor Xa-induced factor Xa genera-
tion curve was found to increase with the hirudin concentration.
Because of the specificity of hirudin for thrombin, there is no
doubt that also in this case a thrombin-catalyzed activation of one
(factor V) or both cofactors is initiating further factor Xa genera-
tion Therefore, the alternative explanation for the observed
effect of exogenous factor Xa might be the ultra sensitivity of the
intrinsic plasma clotting pathway for extremely small changes in
rates of thrombin generation as could be induced by exogenous
factor Xa It is this sensitivity which makes that the anticoagulant
efTectiveness of a certain dose of hirudin during in vitro plasma
clotting is not dependent on the amount of thrombin generated,
but is solely dependent on the rate at which stimulus levels of
thrombin are obtained.
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